← Back to Search

Thyroid Hormone Replacement

Lomustine for Glioblastoma

Phase < 1
Waitlist Available
Led By Alfredo D Voloschin
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to study completion, an average of 2 years
Awards & highlights

Study Summary

This trial tests if a thyroid hormone could help cancer treatment by making patients hypothyroxinemic.

Eligible Conditions
  • Glioblastoma
  • Gliosarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to study completion, an average of 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Secondary outcome measures
Overall response rate
Overall survival
Progression free survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (methimazole, lomustine, liothyronine)Experimental Treatment3 Interventions
See Outline in Detailed Description.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lomustine
2008
Completed Phase 3
~1540
Liothyronine
2015
Completed Phase 3
~310
Methimazole
2006
Completed Phase 4
~710

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,667 Total Patients Enrolled
322 Trials studying Glioblastoma
23,115 Patients Enrolled for Glioblastoma
Emory UniversityLead Sponsor
1,636 Previous Clinical Trials
2,560,573 Total Patients Enrolled
11 Trials studying Glioblastoma
348 Patients Enrolled for Glioblastoma
Alfredo D VoloschinPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma
Jeffrey James Olson 2021. "Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05017610.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top